多西他赛在肝癌介入化疗中的近期疗效评价

The short term efficacy of docetaxel in interventional chemotherapy for hepatic carcinoma

目的评价多西他赛在肝癌介入化疗中的安全性和近期疗效。方法选择106例肝癌患者为研究对象,随机分为对照组49例(采用奥沙利铂和氟尿嘧啶的方案经导管肝动脉介入化疗)、研究组57例(采用多西他赛加奥沙利铂和氟尿嘧啶的方案经导管肝动脉介入化疗),随访1个月观察其疗效及不良反应情况。结果以瘤体改变、腹水及血甲胎蛋白(AFP)改变评价疗效,对照组与研究组治疗有效率分别为68.8%与85.7%、72.0%与96.6%、80.0%与87.8%。对照组与研究组血胆红素和谷草转氨酶的降低值分别为(62.00±3.60)μmol/L与(69.50±4.10)μmol/L、(43.30±2.10)U/L与(49.50±2.20)U/L;两组患者术前生活质量评分分别为(62.00±3.50)分与(61.30±4.00)分,术后评分分别为(67.50±6.00)分与(75.00±5.00)分。其中两组瘤体缩小、腹水消退有效率,血胆红素和转氨酶降低值以及生活质量评分比较,差异有统计学意义,而两组AFP阳性率差异无统计学意义。两组不良反应差异无统计学意义。结论加用多西他赛可以增强肝癌介入化疗的疗效,同时没有加重不良反应。

Objective To evaluate the safety and short term efficacy of docetaxel in interventional chemotherapy for hepatoeellular careinoma（HCC）.Metbods A total of 106 cases of HCC were recruited in the study. They were randomly divided into two groups. The control group （n=49） were given oxaliplatin and fiuorouracil transcatheter hepatic arterial in- fusion chemotherapy and the study group （n=57） were given doeetaxel,platinum and fluorouracil transcatheter hepatic arterial infusion chemotherapy. The efficacy and adverse events were observed in 1 month. Results The effective rates of the size of tumor, ascites and AFP in two groups were 68.8% and 85.7%, 72.00/0 and 96.6%, 80.0% and 87.8% respectively. The depresses of serum bilirubin and aspartate transaminase in two groups were （62.00 ± 3.60） μmol/L and （69.50±4.10）μmol/L, （43.30±2.10） U/L and （49.50±2.20）U/L respectively. The preoperative life quality scores in two groups were （62.00±3.50） points and （61.30±4.00） points,postoperative scores were （67.50±6.00） points and（75.00±5.00） points. There were statistically significant differences between the two groups in the size of tumor, ascites, serum bilirubin, transaminase and patient＇s quality of life scores. However, there was no significant difference between the two groups of AFP variation and the side effects. Conclusion Doeetaxel can enhance the efficacy for HCC with interven- tional chemotherapy. And it did not increase the incidence of adverse reactions.